Session Abstract – PMWC 2020 Silicon Valley


Healthcare diagnostics is at the core of clinical decision making. Early diagnosis can increase the chances of a positive outcome, helping to improve the lives of patients and save payers the costs of further treatment. As health systems move from treatment to prevention, and from volume to value, diagnostics can accelerate this shift. Investment in innovative lab services and technologies is critical in enabling hospitals and healthcare systems to improve efficiencies in the lab, optimize their laboratories to realize gains, and deliver on the imperatives of improving patient outcomes while reducing costs. This session will provide insights from payers that have been actively investing in companies developing innovative lab services and technologies.

 Session Chair Profile

M.D., Managing Director, BlueCross BlueShield Venture Partners

Biography
Tom Hawes serves on the Board of Directors of AbleTo, Octave Bio, Oncology Analytics, Patientco, Upward Health, and Verata as well as board observer for HeartFlow, Healthify, Phreesia, and Thrive Science. He was formerly on the Board of InVivoLink, Nexidia, and Wellspring Healthcare. Before joining Sandbox, Tom matched at Yale School of Medicine for residency and completed his first year of medical training at Greenwich Hospital. During his medical training, he worked on clinical studies at the ISK Institute for Orthopaedics and Sports Medicine and on outcomes research at the National Cancer Institute and NYMC’s Cardiothoracic Surgery Department. Tom holds a BA from Brigham Young University, an M.D. from New York Medical College and an MBA from Harvard Business School. He is also a Kauffman Fellow.


 Speaker Profile

CEO, Thrive Earlier Detection Corp.

Biography
Dave brings to Thrive more than 25 years of diagnostics expertise in significant executive leadership roles in both startup and large-scale organizations. He currently serves as the Chief Executive Officer and Board Member for Thrive Earlier Detection. Prior to Thrive, he served as senior vice president and general manager of commercial operation for the Americas region at Illumina. There, Dave was responsible for all regional commercial functions, including sales, sales support, marketing, field service, technical support and field applications. Prior to joining Illumina, Dave was the chief commercial officer of Foundation Medicine, a company dedicated to transforming cancer care by identifying molecular alterations in each patient’s unique cancer and matching them with potential targeted therapies and immunotherapies. There, he led all commercial functions globally, including sales, marketing, client services, payer relations and medical affairs. Before that, Dave lead the oncology business unit at Life Technologies, responsible for the establishment of a clinical oncology strategy, centered on a central lab services model providing support to both research and clinical customers. After Thermo Fisher acquired Life Technologies, he transitioned to Thermo’s anatomic pathology division, where he oversaw all commercial operations globally.


 Speaker Profile

CEO, Founder, Octave BioSciences

Biography
Bill has more than 25 years of start-up experience in a broad range of medical specialties intersecting science, technology, clinical medicine, and business strategy. Prior to founding Octave Bioscience, he served as the CEO of Crescendo Bioscience which created novel measurement tools and software in the field of rheumatology. Prior to this, he was the President of Alpha BioPartners, a strategic consulting firm advising the launch of new life sciences companies. While at Alpha BioPartners, Bill created the business plan for Crescendo and co-founded Altheus Therapeutics and Biolytx Pharmaceuticals. Prior to that, he served as the initial CEO of Selexys Pharmaceuticals and interim CEO of Inoveon in ophthalmology. In the 1990s, Bill was Chairman and CEO of UroCor, a urology specialty diagnostics company which he scaled from start-up through IPO. Earlier in his career, he was Vice President of Baxter International’s $1.0 billion Scientific Products Division and held management positions at the American Hospital Supply and Becton Dickinson. He currently serves on the board of directors for CareDx, Navican, Genalyte and CoFactor. Previously he was on the board of Prometheus Laboratories. Bill holds a BS in Business Management from Bob Jones University.